Troels Holz Borch

2.0k total citations
42 papers, 1.1k citations indexed

About

Troels Holz Borch is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Troels Holz Borch has authored 42 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 29 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Troels Holz Borch's work include CAR-T cell therapy research (33 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Immunotherapy and Immune Responses (26 papers). Troels Holz Borch is often cited by papers focused on CAR-T cell therapy research (33 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Immunotherapy and Immune Responses (26 papers). Troels Holz Borch collaborates with scholars based in Denmark, Netherlands and Sweden. Troels Holz Borch's co-authors include Inge Marie Svane, Marco Donia, Özcan Met, Mads Hald Andersen, Rikke Andersen, Eva Ellebæk, Trine Zeeberg Iversen, Per Kongsted, Helle Westergren Hendel and Per thor Straten and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Troels Holz Borch

39 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Troels Holz Borch Denmark	19	879	738	202	108	75	42	1.1k
Michelle R. Padget United States	15	724 0.8×	579 0.8×	267 1.3×	59 0.5×	85 1.1×	22	1.0k
Marie Christine Wulff Westergaard Denmark	16	602 0.7×	482 0.7×	178 0.9×	76 0.7×	72 1.0×	24	831
Anthony Miliotto United States	13	559 0.6×	570 0.8×	255 1.3×	81 0.8×	63 0.8×	23	866
Marco Greppi Italy	13	692 0.8×	946 1.3×	228 1.1×	29 0.3×	85 1.1×	24	1.3k
Betty Li United States	13	447 0.5×	512 0.7×	186 0.9×	72 0.7×	46 0.6×	30	755
María Ochoa de Olza Spain	14	521 0.6×	275 0.4×	159 0.8×	82 0.8×	152 2.0×	30	724
Lavakumar Karyampudi United States	10	639 0.7×	744 1.0×	197 1.0×	20 0.2×	81 1.1×	15	963
Parisa Malekzadeh United States	7	651 0.7×	377 0.5×	196 1.0×	101 0.9×	46 0.6×	14	795
Welby Montalvo-Ortiz United States	4	993 1.1×	993 1.3×	159 0.8×	42 0.4×	96 1.3×	5	1.3k
Xuexiang Du United States	10	586 0.7×	504 0.7×	204 1.0×	96 0.9×	59 0.8×	21	856

Countries citing papers authored by Troels Holz Borch

Since Specialization

Citations

This map shows the geographic impact of Troels Holz Borch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Troels Holz Borch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Troels Holz Borch more than expected).

Fields of papers citing papers by Troels Holz Borch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Troels Holz Borch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Troels Holz Borch. The network helps show where Troels Holz Borch may publish in the future.

Co-authorship network of co-authors of Troels Holz Borch

This figure shows the co-authorship network connecting the top 25 collaborators of Troels Holz Borch. A scholar is included among the top collaborators of Troels Holz Borch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Troels Holz Borch. Troels Holz Borch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borch, Troels Holz, Rikke Andersen, Helle Westergren Hendel, et al.. (2025). Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes. Journal for ImmunoTherapy of Cancer. 13(2). e010575–e010575. 1 indexed citations

Borch, Troels Holz, et al.. (2025). Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report. Melanoma Research. 35(5). 344–346.

Klobuch, Sebastian, Maartje W. Rohaan, Troels Holz Borch, et al.. (2025). The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma. European Journal of Cancer. 227. 115640–115640.

Santiago, Marta Velasco, Evelina Martinenaite, Troels Holz Borch, et al.. (2025). Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes. Clinical & Experimental Immunology. 219(1). 2 indexed citations

Borch, Troels Holz, et al.. (2023). TIL Therapy: Facts and Hopes. Clinical Cancer Research. 29(17). 3275–3283. 62 indexed citations

Svane, Inge Marie, et al.. (2023). 66MO Early complete metabolic response predicts long-term efficacy after adoptive cell therapy using tumor-infiltrating lymphocytes. Immuno-Oncology Technology. 20. 100538–100538. 1 indexed citations

Rohaan, Maartje W., Lonneke V. van de Poll‐Franse, Troels Holz Borch, et al.. (2023). “One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care. Journal of Cancer Survivorship. 19(1). 109–120. 2 indexed citations

Granhøj, Joachim Stoltenborg, Troels Holz Borch, Marco Donia, et al.. (2023). Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes. Frontiers in Immunology. 14. 1 indexed citations

Borch, Troels Holz, Katja Harbst, Rikke Andersen, et al.. (2021). Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. Journal for ImmunoTherapy of Cancer. 9(7). e002703–e002703. 21 indexed citations

10.

Kverneland, Anders, Christopher A. Chamberlain, Troels Holz Borch, et al.. (2021). Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for ImmunoTherapy of Cancer. 9(10). e003499–e003499. 45 indexed citations

11.

Kverneland, Anders, Troels Holz Borch, Joachim Stoltenborg Granhøj, et al.. (2021). Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition. Cytotherapy. 23(8). 724–729. 4 indexed citations

12.

Harbst, Katja, Troels Holz Borch, Marie Christine Wulff Westergaard, et al.. (2020). CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Scientific Reports. 10(1). 3914–3914. 50 indexed citations

13.

Kverneland, Anders, Troels Holz Borch, Christopher A. Chamberlain, et al.. (2020). 1022MO Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients. Annals of Oncology. 31. S706–S706. 1 indexed citations

14.

Andersen, Rikke, Troels Holz Borch, Arianna Draghi, et al.. (2018). T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Annals of Oncology. 29(7). 1575–1581. 51 indexed citations

15.

Pedersen, Magnus, Marie Christine Wulff Westergaard, Morten Nielsen, et al.. (2017). Adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic ovarian cancer: A pilot study. Annals of Oncology. 28. v407–v407. 11 indexed citations

16.

Kongsted, Per, Troels Holz Borch, Eva Ellebæk, et al.. (2017). Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. Cytotherapy. 19(4). 500–513. 69 indexed citations

17.

Andersen, Rikke, Marco Donia, Eva Ellebæk, et al.. (2016). Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research. 22(15). 3734–3745. 234 indexed citations

18.

Donia, Marco, Troels Holz Borch, Özcan Met, et al.. (2016). Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.. Journal of Clinical Oncology. 34(15_suppl). TPS9592–TPS9592. 4 indexed citations

19.

Ahmad, Shamaila Munir, Evelina Martinenaite, Morten Hansen, et al.. (2016). PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. OncoImmunology. 5(8). e1202391–e1202391. 30 indexed citations

20.

Borch, Troels Holz, Lotte Engell-Noerregaard, Trine Zeeberg Iversen, et al.. (2016). mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology. 5(9). e1207842–e1207842. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact